Biomarkers of tobacco smoke exposure in racial/ethnic groups at high risk for lung cancer

American Journal of Public Health

Volumn 105, Issue 6, 2015, Pages 1237-1245

  Fagan, Pebbles ^a   Moolchan, Eric T ^b   Pokhrel, Pallav ^a   Herzog, Thaddeus ^a   Cassel, Kevin D ^a   Pagano, Ian ^a   Franke, Adrian A ^a   Kaholokula, Joseph KeawE'Aimoku ^c   Sy, Angela ^d   Alexander, Linda A ^e   Trinidad, Dennis R ^f   Sakuma, Kari Lyn ^g   Johnson, C Anderson ^f   Antonio, Alyssa ^a   Jorgensen, Dorothy ^a   Lynch, Tania ^a   Kawamoto, Crissy ^a   Clanton, Mark S ^h  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b University of Hawaii at Manoa ^*  (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d University of Hawaii at Manoa School of Nursing and Dental Hygiene   (United States)

^e UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^f CLAREMONT GRADUATE UNIVERSITY   (United States)

^g OREGON STATE UNIVERSITY   (United States)

^h TMF Health Quality Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COTININE; HYDROXYCOTININE; NICOTINE;

ADOLESCENT; ADULT; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CAUCASIAN; CHEMISTRY; ETHNOLOGY; FEMALE; HUMAN; LUNG NEOPLASMS; MALE; MASS SPECTROMETRY; OCEANIC ANCESTRY GROUP; PHILIPPINES; RISK; SALIVA; SMOKING; TRANSLATIONAL RESEARCH; UNITED STATES;

ADOLESCENT; ADULT; BIOMARKERS; COTININE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HAWAII; HUMANS; LUNG NEOPLASMS; MALE; MASS SPECTROMETRY; NICOTINE; OCEANIC ANCESTRY GROUP; PHILIPPINES; RISK; SALIVA; SMOKING; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84929353342     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2014.302492     Document Type: Article

References (66)

1. US Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Washington, DC: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.
2. Hawaii cancer facts and figures 2010. Available at: http://www.uhcancercenter.org/pdf/hcff-pub-2010.pdf. Accessed October 30, 2012.
3. Haiman CA, Stram DO, Wilkens LR, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med. 2006;354(4):333-342.
4. Herzog TA, Pokhrel P. Ethnic differences in smoking rate, nicotine dependence, and cessation-related variables among adult smokers in Hawaii. J Community Health. 2012;37(6):1226-1233.
5. US Department of Health and Human Services. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
6. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther. 1997;282(3):1608-1614.
7. Hukkanen J, Jacob P 3rd, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57(1):79-115.
8. Benowitz NL, Jacob P III. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther. 1994;56(5):483-493.
9. Nakajima M, Yamamoto T, Nunoya K, et al. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther. 1996;277(2):1010-1015.
10. Zhu AZ, Zhou Q, Cox LS, Ahluwalia JS, Benowitz NL, Tyndale RF. Variation in trans-3′-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake. PLoS ONE. 2013;8(8):e70938.
11. Dempsey D, Tutka P, Jacob P 3rd, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004;76(1):64-72.
12. Mwenifumbo JC, Al Koudsi N, Ho MK, et al. Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum Mutat. 2008;29(5):679-688.
13. Malaiyandi V, Goodz SD, Sellers EM, Tyndale RF. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1812-1819.
14. Johnstone E, Benowitz N, Cargill A, et al. Determinants of the rate of nicotine metabolism and effects on smoking behavior. Clin Pharmacol Ther. 2006;80(4):319-330.
15. Ho MK, Mwenifumbo JC, Al Koudsi N, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther. 2009;85(6):635-643.
16. Benowitz NL, Pomerleau OF, Pomerleau CS, Jacob P 3rd. Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine Tob Res. 2003;5(5):621-624.
17. Kamataki T, Fujieda M, Kiyotani K, Iwano S, Kunitoh H. Genetic polymorphism of CYP2A6 as one of the potential determinants of tobacco-related cancer risk. Biochem Biophys Res Commun. 2005;338(1):306-310.
18. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer. 2003;3(10):733-744.
19. Yamazaki H, Inui Y, Yun CH, Guengerich FP, Shimada T. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis. 1992;13(10):1789-1794.
20. Zhu AZ, Binnington MJ, Renner CC, et al. Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. Carcinogenesis. 2013;34(1):93-101.
21. Benowitz NL, Jacob P 3rd, Perez-Stable E. CYP2D6 phenotype and the metabolism of nicotine and cotinine. Pharmacogenetics. 1996;6(3):239-242.
22. Ariyoshi N, Miyamoto M, Umetsu Y, et al. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol Biomarkers Prev. 2002;11(9):890-894.
23. Fujieda M, Yamazaki H, Saito T, et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis. 2004; 25(12):2451-2458.
24. Rubinstein ML, Shiffman S, Rait MA, Benowitz NL. Race, gender, and nicotine metabolism in adolescent smokers. Nicotine Tob Res. 2013;15(7):1311-1315.
25. Pérez-Stable EJ, Herrera B, Jacob P III, Benowitz NL. Nicotine metabolism and intake in Black and White smokers. JAMA. 1998;280(2):152-156.
26. Caraballo RS, Giovino GA, Pechacek TF, et al. Racial and ethnic differences in serum cotinine levels of cigarette smokers: Third National Health and Nutrition Examination Survey, 1988-1991. JAMA. 1998;280(2):135-139.
27. Kandel DB, Hu MC, Schaffran C, Udry JR, Benowitz NL. Urine nicotine metabolites and smoking behavior in a multiracial/multiethnic national sample of young adults. Am J Epidemiol. 2007;165(8):901-910.
28. Djordjevic N, Carrillo JA, van den Broek MP, et al. Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans. Drug Metab Pharmacokinet. 2013;28(2):93-97.
29. American Cancer Society. Cancer Facts and Figures 2014. Atlanta, GA: American Cancer Society; 2014.
30. Ramo DE, Rodriguez TM, Chavez K, Sommer MJ, Prochaska JJ. Facebook recruitment of young adult smokers for a cessation trial: methods, metrics, and lessons learned. Internet Interv. 2014;1(2):58-64.
31. Ramo DE, Prochaska JJ. Broad reach and targeted recruitment using Facebook for an online survey of young adult substance use. J Med Internet Res. 2012;14(1):e28.
32. Ramo DE, Hall SM, Prochaska JJ. Reaching young adult smokers through the Internet: comparison of three recruitment mechanisms. Nicotine Tob Res. 2010;12(7):768-775.
33. 2010-2011 Tobacco use supplement to the Current Population Survey. Available at: http://riskfactor.cancer.gov/studies/tus-cps/info.html. Accessed March 20, 2014.
34. Fagerström KO. Measuring degree of physical dependence to tobacco smoking with reference to individualization of treatment. Addict Behav. 1978;3(3-4):235-241.
35. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-1127.
36. Dijkstra A, Tromp D. Is the FTND a measure of physical as well as psychological tobacco dependence? J Subst Abuse Treat. 2002;23(4):367-374.
37. Williams DR, Yu Y, Jackson JS, Anderson NB. Racial differences in physical and mental health: Socioeconomic status, stress, and discrimination. J Health Psychol. 1997;2(3):335-351.
38. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983;24(4):385-396.
39. Shakleya DM, Huestis MA. Simultaneous and sensitive measurement of nicotine, cotinine, trans-3′-hydroxycotinine and norcotinine in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877(29):3537-3542.
40. nd ed. Cary, NC: SAS Institute; 2011.
41. Levi M, Dempsey DA, Benowitz NL, Sheiner LB. Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application. J Pharmacokinet Pharmacodyn. 2007;34(1):23-34.
42. Benowitz NL, Pérez-Stable EJ, Herrera B, Jacob P 3rd. Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J Natl Cancer Inst. 2002;94(2):108-115.
43. Benowitz NL, Dains KM, Dempsey D, Havel C, Wilson M, Jacob P 3rd. Urine menthol as a biomarker of mentholated cigarette smoking. Cancer Epidemiol Biomarkers Prev. 2010;19(12):3013-3019.
44. Ahijevych K, Parsley LA. Smoke constituent exposure and stage of change in Black and White women cigarette smokers. Addict Behav. 1999;24(1):115-120.
45. Boffetta P, Clark S, Shen M, Gislefoss R, Peto R, Andersen A. Serum cotinine level as predictor of lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2006; 15(6):1184-1188.
46. Benowitz NL, Dains KM, Dempsey D, Wilson M, Jacob P. Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure. Nicotine Tob Res. 2011;13(9):772-783.
47. Swan GE, Benowitz NL, Lessov CN, Jacob P 3rd, Tyndale RF, Wilhelmsen K. Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet Genomics. 2005;15(2):115-125.
48. Xu C, Goodz S, Sellers EM, Tyndale RF. CYP2A6 genetic variation and potential consequences. Adv Drug Deliv Rev. 2002;54(10):1245-1256.
49. Conklin BS, Zhao W, Zhong DS, Chen C. Nicotine and cotinine up-regulate vascular endothelial growth factor expression in endothelial cells. Am J Pathol. 2002;160(2):413-418.
50. Heeschen C, Weis M, Aicher A, Dimmeler S, Cooke JP. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin Invest. 2002;110(4):527-536.
51. Li XW, Wang H. Non-neuronal nicotinic alpha 7 receptor, a new endothelial target for revascularization. Life Sci. 2006;78(16):1863-1870.
52. Ng MK, Wu J, Chang E, et al. A central role for nicotinic cholinergic regulation of growth factor-induced endothelial cell migration. Arterioscler Thromb Vasc Biol. 2007;27(1):106-112.
53. Maneckjee R, Minna JD. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci U S A. 1990;87(9):3294-3298.
54. Maneckjee R, Minna JD. Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Differ. 1994;5(10):1033-1040.
55. Cardinale A, Nastrucci C, Cesario A, Russo P. Nicotine: specific role in angiogenesis, proliferation and apoptosis. Crit Rev Toxicol. 2012;42(1):68-89.
56. Dasgupta P, Chellappan SP. Nicotine-mediated cell proliferation and angiogenesis: new twists to an old story. Cell Cycle. 2006;5(20):2324-2328.
57. Carlisle DL, Liu X, Hopkins TM, Swick MC, Dhir R, Siegfried JM. Nicotine activates cell-signaling pathways through muscle-type and neuronal nicotinic acetylcholine receptors in non-small cell lung cancer cells. Pulm Pharmacol Ther. 2007;20(6):629-641.
58. Paleari L, Catassi A, Ciarlo M, et al. Role of alpha7-nicotinic acetylcholine receptor in human non-small cell lung cancer proliferation. Cell Prolif. 2008;41(6):936-959.
59. Dasgupta P, Rastogi S, Pillai S, et al. Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest. 2006;116(8):2208-2217.
60. Benowitz NL, Dains KM, Dempsey D, Herrera B, Yu L, Jacob P 3rd. Urine nicotine metabolite concentrations in relation to plasma cotinine during low-level nicotine exposure. Nicotine Tob Res. 2009;11(8):954-960.
61. Benowitz NL, Jacob P 3rd. Nicotine and cotinine elimination pharmacokinetics in smokers and non-smokers. Clin Pharmacol Ther. 1993;53(3):316-323.
62. Herning RI, Jones RT, Benowitz NL, Mines AH. How a cigarette is smoked determines blood nicotine levels. Clin Pharmacol Ther. 1983;33(1):84-90.
63. Winders SE, Grunberg NE, Benowitz NL, Alvares AP. Effects of stress on circulating nicotine and cotinine levels and in vitro nicotine metabolism in the rat. Psychopharmacology (Berl). 1998;137(4):383-390.
64. Salas R, De Biasi M. Opposing actions of chronic stress and chronic nicotine on striatal function in mice. Neurosci Lett. 2008;440(1):32-34.
65. Krueger PM, Saint Onge JM, Chang VW. Race/ethnic differences in adult mortality: the role of perceived stress and health behaviors. Soc Sci Med. 2011;73(9):1312-1322.
66. Fernander AF, Shavers VL, Hammons GJ. A biopsychosocial approach to examining tobacco-related health disparities among racially classified social groups. Addiction. 2007;102(suppl 2):43-57.